GSK at ERS
INTERNATIONAL CONGRESS 2019
MADRID Spain, 28 Sept - 2 Oct
Visit GSK (G.02 and H.01) to find out about our innovative science. Be sure to attend our three symposia and don't miss our daily lunchtime forum discussions with subject matter experts. This year we mark 50 years of respiratory innovation. We welcome you to help us begin our next 50 years of innovation, living every breath.
Not going to ERS? Register for webcasts of symposia, and see our daily highlights.
SCHEDULE OF EVENTS
Sun 29 Sept
Evening Symposium Can a reduction in risk lead to an improvement in asthma control?
Respiratory Forum at GSK stand
12:45 − 14:45
Sun 29 Sept
Evening Symposium Can a reduction in risk lead to an improvement in asthma control?
Key Speakers
Time
Can a reduction in risk lead to an improvement in asthma control?
Speakers
17:15 − 17:25
Chairman’s introduction
Dr. Luis Perez de Llano
Dr. David Leather
17:25 − 17:45
Why at all stages of disease do we need to strive to gain asthma control
Prof. Andrew Greening
17:45 − 18:05
Learning from the past to advance and optimise care:
Don’t forget the things we have already learned
Prof. Tari Haahtela
18:05 − 18:25
Evidence of effectiveness in asthma
Prof. Ashley Woodcock
18:25 − 18:55
Why striving for effectiveness in maintenance therapy could lead to a reduction in risk
Prof. Huib Kerstjens
18:55 − 19:15
Q&A
Dr. Luis Perez de Llano
Dr. David Leather
17:15 − 17:25
Dr. Luis Perez de Llano
Dr David Leather
Chairman’s introduction
17:25 − 17:45
Prof. Andrew Greening
Why at all stages of disease do we need to strive to gain asthma control
17:45 − 18:05
Prof. Tari Haahtela
Learning from the past to advance and optimise care: Don’t forget the things we have already learned
18:05 − 18:25
Prof. Ashley Woodcock
Evidence of effectiveness in asthma
18:25 − 18:55
Prof. Huib Kerstjens
Why striving for effectiveness in maintenance therapy could lead to a reduction in risk
18:55 − 19:15
Dr. Luis Perez de Llano
Dr David Leather
Q&A
Description
We will discuss the importance of designing drugs for effectiveness — including the use of potent molecules that provide proven efficacy and reduced safety issues — as well as the factors that can drive increased asthma control.
RESPIRATORY FORUMS
Discuss the latest key areas of interest with GSK global medical experts, live on our Commercial stand.
Discussion Themes
Time
Speakers
A treatable traits approach to management of the symptomatic breathless patient: learnings from the recent EMAX trial
12:45 − 13:15
Professor Claus
Vogelmeier (Germany)
▼ Nucala (Mepolizumab) : The long-term efficacy evidence supporting clinician’s choice
13:30 − 14:00
Professor Peter
Howarth (GSK)
A treatable traits approach to managing the patient at risk of exacerbations: the latest data from the IMPACT trial
14:15 − 14:45
Dr Neil Martin (GSK)
12:45 − 13:15
Professor Claus
Vogelmeier (Germany)
A treatable traits approach to management of the symptomatic breathless patient: learnings from the recent EMAX trial
13:30 − 14:00
Professor Peter
Howarth (GSK)
▼ Nucala (Mepolizumab) : The long-term efficacy evidence supporting clinician’s choice
14:15 − 14:45
Dr Neil Martin (GSK)
A treatable traits approach to managing the patient at risk of exacerbations: the latest data from the IMPACT trial
Mon 30 Sept
Evening Symposium Are we doing too little too late in COPD management?
Respiratory Forum at GSK stand
12:45 − 14:45
Mon 30 Sept
Evening Symposium Are we doing too little too late in COPD management?
Key Speakers
Time
Are we doing too little too late in COPD management?
Speakers
17:15 − 17:25
Co-Chair’s introduction
Prof. Alvar Agusti
Co-Chair
17:25 − 17:40
Are others doing better: Can we learn from cardiologists?
Prof. David Newby
17:40 − 18:00
Can we more effectively manage COPD symptoms?
Prof. François Maltais
18:00 − 18:10
Q&A
Led by Prof. Paul Jones
and Prof. Alvar Agusti
18:10 − 18:35
Can we better manage the risk of future COPD exacerbations?
Prof. Mark Dransfield
18:35 − 18:55
Why early optimisation of the treatment of COPD matters
Prof. Neil Barnes
18:55 − 19:00
Drawing it all together: Call to Action
Prof. Paul Jones
19:00 − 19:15
Q&A
Led by Prof. Paul Jones
and Prof. Alvar Agusti
17:15 − 17:25
Prof. Alvar Agusti
Co-Chair
Co-Chair’s introduction
17:25 − 17:40
Prof. David Newby
Are others doing better: Can we learn from cardiologists?
17:40 − 18:00
Prof. François Maltais
Can we more effectively manage COPD symptoms?
18:00 − 18:10
Led by Prof. Paul Jones and
Prof. Alvar Agusti
Q&A
18:10 − 18:35
Prof. Mark Dransfield
Can we better manage the risk of future COPD exacerbations?
18:35 − 18:55
Prof. Neil Barnes
Why early optimisation of the treatment of COPD matters
18:55 − 19:00
Prof. Paul Jones
Drawing it all together: Call to Action
19:00 − 19:15
Led by Prof. Paul Jones and
Prof. Alvar Agusti
Q&A
Description
We will consider risk management strategies to manage COPD in patients with cardiovascular disease. We will discuss how to maximise symptom management and prevent future risk of exacerbations. We will also discuss the importance of starting maintenance treatment early.
RESPIRATORY FORUMS
Discuss the latest key areas of interest with GSK global medical experts, live on our Commercial stand.
Discussion Themes
Time
Speakers
A treatable traits approach to management of the symptomatic breathless patient: learnings from the recent EMAX trial
12:45 − 13:15
Dr Neil Martin (GSK)
A treatable traits approach to managing the patient at risk of exacerbations: the latest data from the IMPACT trial
13:30 − 14:00
Professor Neil Barnes
(GSK)
‘Power to Choose’: What does it mean for SEA patients?
14:15 − 14:45
Professor Ian Pavord
(UK)
12:45 − 13:15
Dr Neil Martin (GSK)
A treatable traits approach to management of the symptomatic breathless patient: learnings from the recent EMAX trial
13:30 − 14:00
Professor Neil Barnes
(GSK)
A treatable traits approach to managing the patient at risk of exacerbations: the latest data from the IMPACT trial
14:15 − 14:45
Professor Ian Pavord
(UK)
‘Power to Choose’: What does it mean for SEA patients?
Tues 1 Oct
Evening Symposium Mepolizumab completing the story: Eosinophils, real-world evidence and the power to choose
Respiratory Forum at GSK stand
12:45 − 14:45
Tues 1 Oct
Evening Symposium Mepolizumab completing the story: Eosinophils, real-world evidence and the power to choose
Key Speakers
Time
Session Title
Speakers
17:15 − 17:25
Chair’s introduction
Dr. Santiago Quirce
17:25 − 17:45
Real-world evidence: A clinician’s perspective
Dr. Stephanie Korn
17:45 − 18:05
Discussion: Eosinophils in health and disease
Moderator: Prof. Neil Barnes
Dr. Peter Howarth (GSK)
and Prof. Ian Pavord (UK)
18:05 − 18:25
A positive choice for patients
Prof. Ian Pavord
18:25 − 18:55
Mepolizumab: A new reality for clinicians
Prof. William Busse
18:55 − 19:15
Q&A
Led by Dr. Santiago Quirce
and Prof. Neil Barnes
17:15 − 17:25
Dr. Santiago Quirce
Chair’s introduction
17:25 − 17:45
Dr. Stephanie Korn
Real-world evidence: A clinician’s perspective
17:45 − 18:05
Moderator: Prof. Neil Barnes
Dr. Peter Howarth (GSK)
and Prof. Ian Pavord (UK)

Discussion: Eosinophils in health and disease
18:05 − 18:25
Prof. Ian Pavord
A positive choice for patients
18:25 − 18:55
Prof. William Busse
Mepolizumab: A new reality for clinicians
18:55 − 19:15
Led by Dr. Santiago Quirce
and Prof. Neil Barnes
Q&A
Description
We will present an overview of the long-term evidence supporting the clinical efficacy and safety profile of mepolizumab in patients with severe eosinophilic asthma. We will also examine the profile of patients most likely to benefit from treatment, given the complexity introduced by an increasing number of biologic treatment options for severe asthma sub-types.
Respiratory Forums
Discuss the latest key areas of interest with GSK global medical experts, live on our Commercial stand.
Discussion Themes
Time
Speakers
Nucala : The long-term efficacy evidence supporting clinician’s choice
12:45 − 13:15
Professor William W.
Busse (USA)
Fluticasone furoate: a modern inhaled steroid
13:30 − 14:00
Professor Neil Barnes (GSK) and
Dr Peter Daley-Yates
‘Power to Choose’: What does it mean for SEA patients?
14:15 − 14:45
Professor Kenneth
Chapman (Canada)
12:45 − 13:15
Professor William W.
Busse (USA)
Nucala : The long-term efficacy evidence supporting clinician’s choice
13:30 − 14:00
Professor Neil Barnes (GSK) and
Dr Peter Daley-Yates
Fluticasone furoate: a modern inhaled steroid
14:15 − 14:45
Professor Kenneth
Chapman (Canada)
‘Power to Choose’: What does it mean for SEA patients?
VISIT OUR STAND
See how our approach to respiratory medicine has continued to improve lives of patients everywhere.
COMMERCIAL STAND
COMMERCIAL STAND

Discover how our science and innovations make a difference by increasing disease understanding and identifying and treating the right patient at the right time.


MEDICAL STAND
MEDICAL STAND

Find out how our innovative research is used to improve disease understanding and develop a variety of active and novel pipeline treatments.

DAILY HIGHLIGHTS
DAILY HIGHLIGHTS Each day, we will be recording the day’s events and posting them on our website. Review what has been happening during the day at ERS or catch up on previous day’s highlights.

Las marcas son propiedad del, o están licenciadas al, grupo de compañías GSK.
Ficha técnica de ▼ Anoro
Ficha técnica ▼ Trelegy
Ficha técnica ▼ Nucala
Ficha técnica Relvar Ellipta.

(▼) Este medicamento está sujeto a seguimiento adicional, es prioritaria la notificación de sospechas de reacciones adversas asociadas a este medicamento.


Su privacidad es importante para nosotros. Haga click aquí para leer nuestra política de privacidad


UA Julio 2019: PM-ES-RS-WCNT-190002(v1)